Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Smets

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 29, 2016
Conclusions: Calls to action for improving the life of MS patients and their familiesPatrick Vermersch, Louis Smets, Ralf Gold
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 29, 2016
Introduction: Do we need multi-stakeholder colloquia in MS?Patrick Vermersch, Louis Smets, Ralf Gold
Journal of Medical Economics|December 13, 2012
Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in FranceBernard Malavaud, Olivier Cussenot, Nicolas Mottet, et al.
Urology|March 26, 2013
Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?Bertrand Tombal, Gerald L Andriole, Alexandre de la Taille, et al.
Journal of European CME|December 5, 2022
Personalised versus non-individualised case-based CME: A randomised pilot studyHerman Stoevelaar, Amit Bahl, Nicky Helsen, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 29, 2016
Conclusions: Calls to action for improving the life of MS patients and their familiesPatrick Vermersch, Louis Smets, Ralf Gold
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 29, 2016
Introduction: Do we need multi-stakeholder colloquia in MS?Patrick Vermersch, Louis Smets, Ralf Gold
Journal of Medical Economics|December 13, 2012
Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in FranceBernard Malavaud, Olivier Cussenot, Nicolas Mottet, et al.
Urology|March 26, 2013
Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?Bertrand Tombal, Gerald L Andriole, Alexandre de la Taille, et al.
Journal of European CME|December 5, 2022
Personalised versus non-individualised case-based CME: A randomised pilot studyHerman Stoevelaar, Amit Bahl, Nicky Helsen, et al.
Pageof 1